Galunisertib modifies the liver fibrotic composition in the Abcb4Ko mouse model.

In conclusion, TGF-β inhibition by galunisertib interferes, to some extent, with chronic liver progression, not by reducing the stage of liver fibrosis as measured by different scoring systems, but rather by modulating the biochemical composition of the deposited ECM, likely affecting the fate of non-parenchymal cells.
PMID: 29808285 [PubMed - as supplied by publisher]

Source: Archives of Toxicology - May 28, 2018 Category: Toxicology Authors: Hammad S, Cavalcanti E, Werle J, Caruso ML, Dropmann A, Ignazzi A, Ebert MP, Dooley S, Giannelli G Tags: Arch Toxicol Source Type: research